Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study

Morlán-Coarasa, María José; Arias-Loste, María Teresa; Foz, Víctor Ortiz-García de la; Martínez-Garcia, Obdulia; Alonso-Martín, Carmen; Crespo, Javier; Romero‐Gómez, Manuel; Fábrega, Emilio; Crespo‐Facorro, Benedicto

doi:10.1007/s00213-016-4422-7

Cited by 44 publications

(31 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study showed that the potential for NAFLD in schizophrenia patients receiving antipsychotic medication is higher. But this study examined the incidence of NAFLD using a randomized design in mostly middle-aged schizophrenia patients, and just looked at the effects of specific antipsychotics on Western people 8. In our study, we focused on young male patients with schizophrenia and investigated risk factors other than antipsychotics.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease

Yan¹,

Hou²,

Liang³

2017

NDT

View full text Add to dashboard Cite

ObjectiveIn this study, we compared the prevalence rate of non-alcoholic fatty liver disease (NAFLD) between young males with schizophrenia and the general young males as the control group, and we also investigated the risk factors of NAFLD in young males with schizophrenia.Materials and methodsThis is a large cross-sectional study consisting of the study group and parallel control group. The study group comprises 202 cases of young males with schizophrenia recruited from Liaoning province Demobilized Soldiers Kangning Hospital, and 149 healthy young males were recruited as the control group. The clinical evaluation included Positive and Negative Syndrome Scale (PANSS), basic information, disease-related information, and physical examination information. The laboratory tests included fasting blood glucose, total cholesterol, triglyceride, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). The physical examination included liver ultrasonography.ResultsNo statistical difference was observed between the study and control groups regarding age (30.5±3.9 vs 30.7±3.6), body mass index (BMI), blood pressure, fasting glucose level, and total cholesterol. NAFLD was observed in both the study and control groups. The prevalence of NAFLD was 49.5% (100/202) in the study group, and 20.1% (30/149) in the control group. The study group was further divided into NAFLD group and non-NAFLD group. There were significant differences in medication combination, drug dosage, negative factor score in PANSS (14.1±4.0 vs 12.7±4.5), BMI, fasting glucose level, total cholesterol, triglyceride, ALT, and AST between NAFLD group and non-NAFLD group. According to the results of the multiple-factor analysis, the onset of NAFLD among young males with schizophrenia was significantly correlated with the following factors: triglyceride, BMI, medication combination, drug dosage, and negative factor score in PANSS.ConclusionThe prevalence of NAFLD in the study group was significantly higher than that in the control group. Multivariate analysis indicated that, triglyceride, BMI, medication combination, drug dosage, and negative factor score in PANSS were significantly related to NAFLD in patients with schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The previous study showed that the potential for NAFLD in first episode schizophrenia spectrum patients was increased after receiving antipsychotic medication for 3 years 8. Remarkable negative symptoms are common in the male patient with schizophrenia, which generally appear in early adulthood.…”

Section: Introductionmentioning

confidence: 99%

The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease

Yan¹,

Hou²,

Liang³

2017

NDT

View full text Add to dashboard Cite

show abstract

“…SGAs have been associated with chronic liver disease in patients with BD in a large observational study 161. During the first 3 years of antipsychotic treatment in patients with the first-episode schizophrenia, nonalcoholic fatty liver disease was associated with the presence of the major components of metabolic syndrome in an RCT 162. Liver function should be monitored in patients administered SGAs 163.…”

Section: Methodsmentioning

confidence: 99%

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Solmi

Murru

Pacchiarotti

et al. 2017

TCRM

324

244

View full text Add to dashboard Cite

Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients – psychosocial functioning, quality of life, and recovery. These drugs are no longer limited to specific Diagnostic and Statistical Manual of Mental Disorders (DSM) categories. Evidence indicates that SGAs show an improved safety and tolerability profile compared with FGAs. The incidence of treatment-emergent extrapyramidal side effects is lower, and there is less impairment of cognitive function and treatment-related negative symptoms. However, treatment with SGAs has been associated with a wide range of untoward effects, among which treatment-emergent weight gain and metabolic abnormalities are of notable concern. The present clinical review aims to summarize the safety and tolerability profile of selected FGAs and SGAs and to link treatment-related adverse effects to the pharmacodynamic profile of each drug. Evidence, predominantly derived from systematic reviews, meta-analyses, and clinical trials of the drugs amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, CPZ, haloperidol, loxapine, and perphenazine, is summarized. In addition, the safety and tolerability profiles of antipsychotics are discussed in the context of the “behavioral toxicity” conceptual framework, which considers the longitudinal course and the clinical and therapeutic consequences of treatment-emergent side effects. In SMI, SGAs with safer metabolic profiles should ideally be prescribed first. However, alongside with safety, efficacy should also be considered on a patient-tailored basis.

show abstract

“…After 3 months and then yearly for 3 years, they (Morlan-Coarasa M J et al 2016. 34 ) calculated the NAFLD fibrosis score, fibrosis score and FLI at baseline. Finally, through their study they concluded that there is a potential related with the development of NAFLD with schizophrenic patients receiving anti-psychotic medication.…”

Section: Study Reports Related To the Risk Factors And Etiology Ofmentioning

confidence: 99%

A Recent Research on Non Alcoholic Fatty Liver Disease

2019

IJRTE

View full text Add to dashboard Cite

Non alcoholic fatty liver disease (NAFLD) is a persistent condition of liver steatosis in the absence of alcohol consumption. The main risk factors associated with the disease are hypertension, diabetes mellitus and dyslipidemia these are together termed as metabolic syndrome. Recent studies identified that children are more vulnerable to develop NAFLD in future due to sedentary life styles and poor diet. NAFLD can further make complications of cardiovascular and liver related disorders. Apart from these causes there are factors such as enzyme, gene expression; amino acid regulation and so on in the human body plays an important role in the development of NAFLD. The objective of this research is to summaries the various ways by which a NAFLD is affected in a normal individual and to point out current research on treatment strategy for the NAFLD.

show abstract

Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study

Abstract: Our results support the importance of assessing the potential development of NAFLD in schizophrenia spectrum patients receiving antipsychotic medication.

Cited by 44 publications

References 16 publications

The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease

The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

A Recent Research on Non Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About